Evaluating the use of circulating tumor DNA in gastroesophageal cancer
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
This study is testing if measuring circulating tumor DNA can help doctors understand how gastroesophageal cancer is progressing and how well different treatments are working for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1950 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT04576858 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical utility of circulating tumor DNA (ctDNA) in patients with gastroesophageal cancer across five different treatment cohorts. These cohorts include patients undergoing surgical resection with chemotherapy, neoadjuvant chemoradiotherapy, definitive chemoradiotherapy, systemic therapy, and palliative treatment. The study will focus on evaluating treatment effects as well as predictive and prognostic factors associated with ctDNA in plasma. By analyzing ctDNA, the study seeks to enhance understanding of cancer progression and treatment response in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older diagnosed with gastroesophageal cancer.
Not a fit: Patients who are unable to provide informed consent or do not have gastroesophageal cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of treatments for gastroesophageal cancer and improve patient outcomes through personalized medicine.
How similar studies have performed: Other studies have shown promise in using circulating tumor DNA for monitoring cancer treatment, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Gastroesophageal cancer Age 18 years or older Able to understand and sign written informed consent Exclusion Criteria: Patients not providing informed consent
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Study coordinator: Morten Mau-Sørensen, MD, PhD
- Email: mms@rh.regionh.dk
- Phone: 35450879
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.